MMRGlobal Completes Filing of Additional Cancer Fighting Patent in Japan to Pursue Additional Antibody Protection
This filing is in addition to an existing pending application in Japan. As announced earlier this week, in furtherance to antibody patents granted patents in the U.S., Australia and Mexico, an additional patent application was also recently filed in China under the Patent Prosecution Highway Program to expedite the issuance of patents to MMR for its anti-CD20 monoclonal antibodies in the U.S.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.